Novo Nordisk to Test GLP-1 Drugs Against Addiction
Novo Nordisk, maker of Ozempic and Wegovy, says they will start testing GLP-1 drugs for use in treating addiction.
Preventing Relapse During Recovery From Opioid Use Disorder
Researchers at the University of Maryland team up to study the genetics of relapse during recovery from opioid use disorder.
Sleep and Substance Use Disorder
New studies examine the relationship between sleep and substance use disorder.
Does Ozempic Cause Blindness?
A new study from JAMA Ophthalmology reviews nine cases of sudden vision loss associated with taking GLP-1 drugs.
Cannabis Use Disorder Increases Risk of Mortality
A massive study out of Canada shows a threefold increase in five-year mortality for people treated for cannabis use disorder.
Evaluations of the Therapeutic Community in Addiction Treatment
Therapeutic communities or “wellness farms” are in the news. We take a look at their track record.